Get real. If Nader needs this kind of help interpreting the FDA RTF and ontop believes AMAREX that the syringes where the main problem of the BLA, then we shareholders have really a big problem.
Was Nader and Kelly not attending the various FDA meetings before and after the RTF letter? If they did not grasp the magnitude of the BLA deficiencies after the RTF letter, then they are not fit for the job in my opinion.